Pharming Group (CHIX:PHARMA) Long-Term Capital Lease Obligation : €24.5 Mil (As of Mar. 2025)

View and export this data going back to 2008. Start your Free Trial

What is Pharming Group Long-Term Capital Lease Obligation?

Pharming Group's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was €24.5 Mil.

Pharming Group's quarterly Long-Term Capital Lease Obligation increased from Sep. 2024 (€25.0 Mil) to Dec. 2024 (€25.8 Mil) but then declined from Dec. 2024 (€25.8 Mil) to Mar. 2025 (€24.5 Mil).

Pharming Group's annual Long-Term Capital Lease Obligation declined from Dec. 2022 (€28.2 Mil) to Dec. 2023 (€27.1 Mil) and declined from Dec. 2023 (€27.1 Mil) to Dec. 2024 (€25.8 Mil).

Pharming Group Long-Term Capital Lease Obligation Historical Data

The historical data trend for Pharming Group's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Long-Term Capital Lease Obligation Chart

Pharming Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

6.77

16.33

28.17

27.06

25.75

Pharming Group Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															26.16	25.76	25.03	25.75	24.52

Pharming Group (CHIX:PHARMa) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Pharming Group Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Pharming Group's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharming Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (CHIX:PHARMa) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

PHAR:USA PHGUF:USA PHARM:Netherlands 0QCO:UK PHGN:Germany

Address

Darwinweg 24, Leiden, ZH, NLD, 2333 CR

Website

https://www.pharming.com

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Pharming Group Headlines

No Headlines